Cargando…
Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements
For type 2 diabetes mellitus treatment and clinical development, proper evaluation of cardiovascular risk has been required by regulatory agencies (eg, the US Food and Drug Administration) since cardiovascular safety is very important in this patient population. The US Food and Drug Administration i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516202/ https://www.ncbi.nlm.nih.gov/pubmed/26229496 http://dx.doi.org/10.2147/DMSO.S84005 |